Labcorp to Acquire Select BioReference Health Assets from OPKO for $722 Million

Key Facts

1Labcorp entered into an agreement with OPKO Health to acquire select assets of BioReference Health.

Labcorp entered into an agreement with OPKO Health to acquire select assets of its BioReference Health laboratories. PR Newswire reported that the purchase price is $722 million in cash at closing, with an additional earnout of up to $150 million based on the revenue performance of the 4Kscore prostate cancer test.

The acquisition aims to strengthen Labcorp's ability to deliver specialized diagnostic services and broaden patient access to clinical testing across the United States. Regarding market performance, LH closed at $317.34 on October 14, 2026, while OPK closed at $1.37 on the same date.